Merck to acquire SpringWorks Therapeutics for $3.4bn.

Merck, a global pharmaceutical and chemicals company, agreed to acquire SpringWorks Therapeutics, a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, for $3.4bn. “The agreed acquisition of SpringWorks is a major step in our active portfolio strategy to position Merck as a globally diversified, innovation and technology powerhouse. For our Healthcare sector, it sharpens the focus on rare tumors, accelerates growth, and strengthens our presence in the US,” Belén Garijo, Merck Chair of the Executive Board and CEO.